These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 21571506)

  • 1. Remission as perceived by people with schizophrenia, family members and psychiatrists.
    Karow A; Naber D; Lambert M; Moritz S;
    Eur Psychiatry; 2012 Aug; 27(6):426-31. PubMed ID: 21571506
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Remitted but still impaired? Symptomatic versus functional remission in patients with schizophrenia.
    Karow A; Moritz S; Lambert M; Schöttle D; Naber D;
    Eur Psychiatry; 2012 Aug; 27(6):401-5. PubMed ID: 21570262
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment effectiveness in patients with schizophrenia as measured by the ASSESS battery - first longitudinal data.
    Ladea M; Barbu CM; Juckel G
    Psychiatr Danub; 2015 Dec; 27(4):364-70. PubMed ID: 26609648
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quality of life and subjective well-being in schizophrenia and schizophrenia spectrum disorders: valid predictors of symptomatic response and remission?
    Schennach-Wolff R; Jäger M; Obermeier M; Schmauss M; Laux G; Pfeiffer H; Naber D; Schmidt LG; Gaebel W; Klosterkötter J; Heuser I; Kühn KU; Lemke MR; Rüther E; Klingberg S; Gastpar M; Seemüller F; Möller HJ; Riedel M
    World J Biol Psychiatry; 2010 Aug; 11(5):729-38. PubMed ID: 20380620
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Negative symptoms and psychosocial functioning in schizophrenia: neglected but important targets for treatment.
    Hunter R; Barry S
    Eur Psychiatry; 2012 Aug; 27(6):432-6. PubMed ID: 21602034
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is it true remission? A study of remitted patients affected by schizophrenia and schizoaffective disorders.
    Pinna F; Deriu L; Lepori T; Maccioni R; Milia P; Sarritzu E; Tusconi M; Carpiniello B;
    Psychiatry Res; 2013 Dec; 210(3):739-44. PubMed ID: 24007858
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Employment and its relationship with functionality and quality of life in patients with schizophrenia: EGOFORS Study.
    Üçok A; Gorwood P; Karadayı G;
    Eur Psychiatry; 2012 Aug; 27(6):422-5. PubMed ID: 21592736
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Symptomatic resolution among Chinese patients with schizophrenia and associated factors.
    Li CT; Su TP; Chou YH; Lee YC; Liu ME; Ku HL; Shan IK; Bai YM
    J Formos Med Assoc; 2010 May; 109(5):378-88. PubMed ID: 20497871
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Response and remission of subjective well-being in patients suffering from schizophrenia spectrum disorders.
    Schennach-Wolff R; Seemüller F; Obermeier M; Messer T; Laux G; Pfeiffer H; Naber D; Schmidt LG; Gaebel W; Klosterkötter J; Heuser I; Maier W; Lemke MR; Rüther E; Buchkremer G; Gastpar M; Jäger M; Möller HJ; Riedel M
    Eur Psychiatry; 2011; 26(5):284-92. PubMed ID: 20435447
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quality of life and subjective well-being during treatment with antipsychotics in out-patients with schizophrenia.
    Wehmeier PM; Kluge M; Schneider E; Schacht A; Wagner T; Schreiber W
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Apr; 31(3):703-12. PubMed ID: 17289237
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Establishing remission and good clinical functioning in schizophrenia: predictors of best outcome with long-term risperidone long-acting injectable treatment.
    Lambert M; De Marinis T; Pfeil J; Naber D; Schreiner A
    Eur Psychiatry; 2010 May; 25(4):220-9. PubMed ID: 19926263
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The subjective quality of life of patients with schizophrenia: influence of psychopathology and patients' expectations. A comparative study].
    Salomé F; Petitjean F; Germain C; Demant JC
    Encephale; 2004; 30(1):60-8. PubMed ID: 15029078
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A prospective, open-label study to evaluate symptomatic remission in schizophrenia with risperidone long-acting injectable in Korea.
    Lee NY; Kim SH; Cho SJ; Chung YC; Jung IK; Kim CY; Kim DH; Lee DG; Lee YH; Lim WJ; Na YS; Shin SE; Woo JM; Yoon JS; Yoon BH; Ahn YM; Kim YS
    Int Clin Psychopharmacol; 2014 Sep; 29(5):279-87. PubMed ID: 24583566
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Rationale for the use of long-acting injectable risperidone: a survey of French psychiatrists].
    Misdrahi D; Delgado A; Bouju S; Comet D; Chiariny JF
    Encephale; 2013 May; 39 Suppl 1():S8-14. PubMed ID: 23541914
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improvement of subjective well-being and enduring symptomatic remission, a 5-year follow-up of first episode schizophrenia.
    de Haan L; Nimwegen Lv; Amelsvoort Tv; Dingemans P; Linszen D
    Pharmacopsychiatry; 2008 Jul; 41(4):125-8. PubMed ID: 18651339
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Remission in prognosis of functional outcome: a new dimension in the treatment of patients with psychotic disorders.
    Helldin L; Kane JM; Karilampi U; Norlander T; Archer T
    Schizophr Res; 2007 Jul; 93(1-3):160-8. PubMed ID: 17395430
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Subjective assessments of the quality of life, well-being and self-efficacy in patients with schizophrenia.
    Chino B; Nemoto T; Fujii C; Mizuno M
    Psychiatry Clin Neurosci; 2009 Aug; 63(4):521-8. PubMed ID: 19531107
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Criteria for symptom remission revisited: a study of patients affected by schizophrenia and schizoaffective disorders.
    Pinna F; Tusconi M; Bosia M; Cavallaro R; Carpiniello B;
    BMC Psychiatry; 2013 Sep; 13():235. PubMed ID: 24294839
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characteristics of two alternative schizophrenia remission definitions: relationship to clinical and quality of life outcomes.
    Dunayevich E; Sethuraman G; Enerson M; Taylor CC; Lin D
    Schizophr Res; 2006 Sep; 86(1-3):300-8. PubMed ID: 16860974
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Subjective well-being, drug attitude, and changes in symptomatology in chronic schizophrenia patients starting treatment with new-generation antipsychotic medication.
    Widschwendter CG; Kemmler G; Rettenbacher MA; Yalcin-Siedentopf N; Hofer A
    BMC Psychiatry; 2018 Jun; 18(1):212. PubMed ID: 29954366
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.